bioMérieux – Increased outlook for full-year 2022 and 2023 guidance preview

Marcy-l'Étoile, December 15, 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2022 and a preview of 2023 guidance.

INCREASED OUTLOOK FOR FULL YEAR 2022

In light of an unusually early and rapid increase in influenza infections, along with a continued high incidence of respiratory syncytial virus (RSV) and ongoing endemic COVID-19, BIOFIRE® respiratory panel sales will be higher than forecasted in Q4.
Therefore, full-year 2022 net sales are now expected to be stable at constant exchange rates (vs. previously: upper end of -6% to -3% range) and contributive operating income before non-recurring items to be above €660 million (previously: upper end of €580M - €625M range).

PREVIEW OF 2023 GUIDANCE

In 2023, excluding respiratory panels, sales growth is expected to reach +8% to +10% on a like for like basis, driven by a solid growth of BIOFIRE® non-respiratory panels as well as Microbiology and Industrial applications
- Sales of non-respiratory BIOFIRE® panels are expected to pursue a strong growth, around mid-teens in 2023, thanks to their high medical value, the broad menu offering and cross-selling on the large BioFire installed base.
- Sales of Microbiology and Industrial applications are expected to grow high single digit, including price increases, while Immunoassays should return to growth.
- Respiratory panels sales are foreseen to slow down, assuming a medium flu season at the end of 2023 compared to the current strong one in Q4 2022.
Above expected 2023 business trends would lead to total next year sales organic growth evolving within a +4% to +6% range. Contributive operating income before non-recurring items should be within a range of €600 to €630 million, at forecasted exchange rates.
- Sales growth and price increases should almost fully offset cost inflation, while exchange rates effects would be approximately 40 M€ negative.
- bioMérieux will pursue its investment in new products, with several key launches in 2023, to be supported by R&D, commercial operations and medical affairs.

Those 2023 perspectives are subject to revision while communicating our yearly results on March, 8th 2023.

INVESTOR PRESENTATION

A call will take place on December 15th, at 3pm CET to review above perspectives The presentation will be given in English and will be accessible via webcast under following link:

https://globalmeet.webcasts.com/starthere.jsp?ei=1588992&tp\_key=19435a9d74

If you are unable to join the webcast URL, please join audio conference with:.

France	Europe	United States
+33 (0)1 70 72 25 50	+44 (0)330 165 3655	+1 323-994-2093
Access code: 531 1720

INVESTOR CALENDAR

Fourth-quarter 2022 sales and 2022 financial results March 8

th, 2023

Notes and definitions

The above forward-looking statements are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2021 Universal Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.

Currency effect: this is established by converting actual numbers at the average rates of year y-1. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up. Argentina and Turkey are considered in bioMérieux's accounts since 2022 in a state of hyperinflation. Impacts of hyperinflation in accordance with IAS 29 in the Company's accounts are excluded in the calculation of Like-for-Like growth.

Changes in scope of consolidation: these are determined:

for acquisitions in the period, by deducting from sales for the period the amount of sales generated during the period by acquired entities as from the date they entered the consolidated reporting scope;
for acquisitions in the previous period, by deducting from sales for the period the amount of sales generated in the months in the previous period during which the acquired entities were not consolidated;
for disposals in the period, by adding to sales for the period the amount of sales generated by entities sold during the previous period in the months of the current period during which these entities were no longer consolidated;
for disposals in the previous period, by adding to sales for the period the amount of sales generated during the previous period by the entities sold.

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 93% of international sales (outside of France).

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com

CONTACTS

Investor Relations bioMérieux Franck Admant

Tel.: +33 (0)4 78 87 20 00 [email protected]

Media Relations

bioMérieux Image Sept Romain Duchez Laurence Heilbronn Claire Doligez Tel.: +33 (0)4 78 87 20 00 Tel.: +33 (0)1 53 70 74 64 Tel.: +33 (0)1 53 70 74 48 [email protected] [email protected] [email protected]

AI Terminal

bioMérieux

1152_iss_2022-12-15_8b35f4fb-1e26-4667-b006-0b6042d0654e.pdf